Diabetes and Endocrinology - Global Cardiology Academy

1-16 of 30

Addressing Cardiovascular Risk in Prediabetes: Why Earlier Action Matters
Addressing Cardiovascular Risk in Prediabetes: Why Earlier Action Matters
Diabetes Discourse
Addressing Cardiovascular Risk in Prediabetes: Why Earlier Action Matters
John W. Ostrominski, MD, MPH
- John W. Ostrominski, MD, MPH
INFINITY in Focus: Translating New Nonsteroidal MRA Evidence Into Cardiorenal Practice
INFINITY in Focus: Translating New Nonsteroidal MRA Evidence Into Cardiorenal Practice
Nephrology
INFINITY in Focus: Translating New Nonsteroidal MRA Evidence Into Cardiorenal Practice
Peter Rossing, MD, DMSc
- Peter Rossing, MD, DMSc
Real-World Evidence: Effectiveness of Finerenone in Reducing UACR in Patients With CKD and Type 2 Diabetes
Real-World Evidence: Effectiveness of Finerenone in Reducing UACR in Patients With CKD and Type 2 Diabetes
Diabetes and Endocrinology
Real-World Evidence: Effectiveness of Finerenone in Reducing UACR in Patients With CKD and Type 2 Diabetes
Csaba P. Kovesdy, MD
- Csaba P. Kovesdy, MD
FINE-ONE Across the Ages: Evaluating nsMRA Evidence in CKD and Type 1 Diabetes
FINE-ONE Across the Ages: Evaluating nsMRA Evidence in CKD and Type 1 Diabetes
Diabetes and Endocrinology
FINE-ONE Across the Ages: Evaluating nsMRA Evidence in CKD and Type 1 Diabetes
Katherine Tuttle, MD
- Katherine Tuttle, MD
Subcutaneous Lp(a)-Lowering Therapies: Understanding the Evidence
Subcutaneous Lp(a)-Lowering Therapies: Understanding the Evidence
Heart Matters
Subcutaneous Lp(a)-Lowering Therapies: Understanding the Evidence
M. Melih Dogan, MD
- M. Melih Dogan, MD
Complication-Centric Diabetes Care: Addressing Obesity and Cardiometabolic Risk
Complication-Centric Diabetes Care: Addressing Obesity and Cardiometabolic Risk
Heart Matters
Complication-Centric Diabetes Care: Addressing Obesity and Cardiometabolic Risk
Scott D. Isaacs, MD FACP, FACE
- Scott D. Isaacs, MD FACP, FACE
Updated AACE Guidance on Managing Dyslipidemia in T2D
Updated AACE Guidance on Managing Dyslipidemia in T2D
Heart Matters
Updated AACE Guidance on Managing Dyslipidemia in T2D
Scott D. Isaacs, MD FACP, FACE
- Scott D. Isaacs, MD FACP, FACE
Understanding Residual Cardiovascular Risk in CKD and T2D
Understanding Residual Cardiovascular Risk in CKD and T2D
Diabetes Discourse
Understanding Residual Cardiovascular Risk in CKD and T2D
John W. Ostrominski, MD, MPH
- John W. Ostrominski, MD, MPH
Is It Familial or Multifactorial Chylomicronemia Syndrome?
Is It Familial or Multifactorial Chylomicronemia Syndrome?
On the Frontlines of Familial Chylomicronemia Syndrome
Is It Familial or Multifactorial Chylomicronemia Syndrome?
Steve Jackson, PharmD; Michael D. Shapiro
- Steve Jackson, PharmD
- Michael D. Shapiro
A Multi-Pillar Approach to Cardio-Renal Risk Reduction
A Multi-Pillar Approach to Cardio-Renal Risk Reduction
Heart Matters
A Multi-Pillar Approach to Cardio-Renal Risk Reduction
Brian P. McDonough, MD, FAAFP; Anu Lala, MD
- Brian P. McDonough, MD, FAAFP
- Anu Lala, MD
- Martha Gulati, MD, MS, FACC, FAHA
No Patient with CKD Left Behind! Emerging CKD Therapies in T1D
No Patient with CKD Left Behind! Emerging CKD Therapies in T1D
CME/CE
No Patient with CKD Left Behind! Emerging CKD Therapies in T1D
Richard E. Pratley, MD; David Cherney, MD, PhD
0.50 credits
- Richard E. Pratley, MD
- David Cherney, MD, PhD
- prof. Hiddo Heerspink
0.50 credits
Finerenone vs Placebo in Type 1 Diabetes and CKD: Updates From the Phase 3 FINE-ONE Trial From the Kidney Meeting 2025 in Houston
Finerenone vs Placebo in Type 1 Diabetes and CKD: Updates From the Phase 3 FINE-ONE Trial From the Kidney Meeting 2025 in Houston
Nephrology
Finerenone vs Placebo in Type 1 Diabetes and CKD: Updates From the Phase 3 FINE-ONE Trial From the Kidney Meeting 2025 in Houston
prof. Hiddo Heerspink
- prof. Hiddo Heerspink
Implications of the FINE-ONE Trial: How Might Recently Presented Data From the 2025 Kidney Meeting Influence the Current Treatment Paradigm for Type 1 Diabetes and CKD?
Implications of the FINE-ONE Trial: How Might Recently Presented Data From the 2025 Kidney Meeting Influence the Current Treatment Paradigm for Type 1 Diabetes and CKD?
Nephrology
Implications of the FINE-ONE Trial: How Might Recently Presented Data From the 2025 Kidney Meeting Influence the Current Treatment Paradigm for Type 1 Diabetes and CKD?
Richard E. Pratley, MD
- Richard E. Pratley, MD
New Data From the CONFIDENCE Trial: The Effect of Combination Empagliflozin and Finerenone on UACR and eGFR in CKD and Type 2 Diabetes
New Data From the CONFIDENCE Trial: The Effect of Combination Empagliflozin and Finerenone on UACR and eGFR in CKD and Type 2 Diabetes
Nephrology
New Data From the CONFIDENCE Trial: The Effect of Combination Empagliflozin and Finerenone on UACR and eGFR in CKD and Type 2 Diabetes
prof. Hiddo Heerspink
- prof. Hiddo Heerspink
The Impact of Finerenone Plus Empagliflozin on Hyperkalemia in the CONFIDENCE Trial
The Impact of Finerenone Plus Empagliflozin on Hyperkalemia in the CONFIDENCE Trial
Nephrology
The Impact of Finerenone Plus Empagliflozin on Hyperkalemia in the CONFIDENCE Trial
Rajiv Agarwal, MBBS, MD, FASN, BRCU
- Rajiv Agarwal, MBBS, MD, FASN, BRCU
The Hidden Threat: Transforming CKD Care Across the Diabetes Spectrum 
The Hidden Threat: Transforming CKD Care Across the Diabetes Spectrum 
CME/CE
The Hidden Threat: Transforming CKD Care Across the Diabetes Spectrum 
prof. Hiddo Heerspink; Peter Rossing, MD, DMSc
0.50 credits
- prof. Hiddo Heerspink
- Peter Rossing, MD, DMSc
- Paola Fioretto, MD
0.50 credits

Prev
1
2
Next

1/2